Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Corporation to Present at Upcoming Investor Conferences
08 nov. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
01 nov. 2022 07h30 HE
|
Repligen Corporation
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers base business growth of 29% for the...
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
01 nov. 2022 07h00 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company...
Repligen to Report Third Quarter 2022 Financial Results
12 oct. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1,...
Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
19 sept. 2022 16h01 HE
|
Repligen Corporation
WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a...
Repligen To Host Investor Day 2022
24 août 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen...
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
02 août 2022 07h30 HE
|
Repligen Corporation
Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year)Strong organic revenue growth of 29% and strong base...
Repligen to Report Second Quarter 2022 Financial Results
19 juil. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2022 financial results on Tuesday, August 2,...
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
26 mai 2022 16h30 HE
|
Repligen Corporation
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and...